Call for Abstract

16th World Congress on Vascular Dementia and Neurodegenerative Diseases, will be organized around the theme “Creating better knowledge on Dementia and Neurodegenerative diseases”

Vascular Dementia-2019 is comprised of keynote and speakers sessions on latest cutting edge research designed to offer comprehensive global discussions that address current issues in Vascular Dementia-2019

Submit your abstract to any of the mentioned tracks.

Register now for the conference by choosing an appropriate package suitable to you.

Dementia is a chronic or persistent disorder of the mental ability process caused by brain diseases or injuries marked due to personality changes, memory disorders and impaired reasoning. Dementia is not a specific disease. It's a group of symptoms related with a decline in memory or other thinking ability skills enough to reduce a person's ability activities. Various kinds of dementia are associated with particular types of brain cell damage in particular regions of the brain

 

Vascular dementia, which occurs after a stroke, is the second most common dementia type. But there are many other conditions that can cause symptoms of dementia, including some that are reversible, such as thyroid problems and vitamin deficiencies. In vascular dementia, changes in thinking skills sometimes occur suddenly following strokes that block major brain blood vessels. Thinking problems also may begin as mild changes that worsen gradually as a result of multiple minor strokes or other conditions that affect smaller blood vessels, leading to cumulative damage. Vascular dementia symptoms can vary widely, depending on the severity of the blood vessel damage and the part of the brain affected. Memory loss may or may not be a significant symptom depending on the specific brain areas where blood flow is reduced. Symptoms may be most obvious when they happen soon after a major stroke

 

Dementia in stages refers how far a person’s dementia has been progressed. It defines a person’s disease stage helping physicians to determine the best treatment approach and aid communication between health providers and caregivers. Sometimes the stage is simply referred to as “early stage”, “middle stage” or “late-stage” dementia, but often a more exact stage is assigned, based on a person’s symptoms.

 

Neurodegenerative disease is an umbrella term for a range of conditions which primarily affect the neurons in the human brain. Neurons are the building blocks of the nervous system which includes the brain and spinal cord. Neurons normally don’t reproduce or replace themselves, so when they become damaged or die they cannot be replaced by the body. Examples of neurodegenerative diseases include Parkinson’s, Alzheimer’s, and Huntington’s disease.

 

Lewy body is also known as dementia with Lewy bodies, with Lewy body dementia is the second most common type of progressive dementia after Alzheimer's disease dementia. Protein deposits, called Lewy bodies, develop in nerve cells in the brain regions involved in thinking, memory and movement (motor control).

 

Amyloid imaging is a technique performed in nuclear medicine. It uses PET ligands that allow in vivo detection of amyloid plaques, a core pathologic feature of Alzheimer disease and dementia.

Caregivers of dementia patients need to understand dementia so that they can understand what the patient is going through. They need to know about underlying diseases, and how these may affect the progress of dementia. They also need to know what sort of behavior to expect. Understanding these helps them plan for their caregiving and to cope with the situation effectively, and with less stress.

 

Treatment of dementia begins with the treatment of the underlying disease, where possible. The underlying causes of nutritional, hormonal, tumour-caused or drug-related dementia may be reversible to some extent. For many other diseases, such as Alzheimer's disease (AD), no cure has yet been discovered. However, improvement of cognitive and behavioural symptoms can be achieved through a combination of appropriate medications and other treatments, including psychotherapy.

The animal models of dementia and Alzheimer's disease. For pre-clinical testing and clinical translation. Dementia is a clinical syndrome with abnormal degree of memory loss and impaired ability to recall events from the past often characterized by Alzheimer's disease.

 

 

<p justify;\"="">

It is a branch of Medical Sciences majorly deals with Neuro tumors. Deals with Studies related to Brain and Spinal cord neoplasms. Neuro-oncology and Pediatric Neuro-oncology are the two different Concepts that differentiate the determining methodology of Neuro tumors. Neuro-oncology mainly includes especially related topics like Radiation therapy, Neurosurgery, Neuroimaging, social, Psychological, Neuropathology and psychiatric aspects.

 

Neuropharmacology is the scientific study of the effects of drugs on the nervous system. Its primary focus is the actions of medications for psychiatric and neurologic disorders as well as those of drugs of abuse. Drugs that act on the nervous system, including antidepressant, antianxiety, anticonvulsant, and antipsychotic agents, are among the most widely prescribed medications.

 

Vascular cognitive impairment is a decline in thinking abilities caused by disease that damages the brain’s blood vessels. Vascular disease may cause cognitive impairment on its own, and can also contribute to impairments in thinking and behaviour in a person with another brain disease such as Alzheimer’s.

 

Therapeutic targets are bio molecules maybe a nucleic acid or a protein whose biological activity can be modified by a drug candidate. In some cases of Dementia, it is reported that proteins are the cause for the disease. For example the accumulation of amyloid protein in the regions of Brain acts as a major factor for the disorder, hence it can be a therapeutic target. Therapeutic targets play an important role in identifying the potential drug candidates. Hence the conference provides the discussion sessions to reveal the targets for drug design process.